Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2010-2-9
pubmed:abstractText
To determine the pharmacokinetics of gimatecan, a camptothecin with a lipophilic substitution in position 7, given orally to patients participating in the phase I study.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
1879-0852
pubmed:author
pubmed:copyrightInfo
Copyright (c) 2009 Elsevier Ltd. All rights reserved.
pubmed:issnType
Electronic
pubmed:volume
46
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
505-16
pubmed:meshHeading
pubmed-meshheading:20007015-Administration, Oral, pubmed-meshheading:20007015-Adolescent, pubmed-meshheading:20007015-Adult, pubmed-meshheading:20007015-Aged, pubmed-meshheading:20007015-Aged, 80 and over, pubmed-meshheading:20007015-Animals, pubmed-meshheading:20007015-Antineoplastic Agents, Phytogenic, pubmed-meshheading:20007015-Blood Specimen Collection, pubmed-meshheading:20007015-Camptothecin, pubmed-meshheading:20007015-Chromatography, High Pressure Liquid, pubmed-meshheading:20007015-Dose-Response Relationship, Drug, pubmed-meshheading:20007015-Drug Administration Schedule, pubmed-meshheading:20007015-Female, pubmed-meshheading:20007015-Half-Life, pubmed-meshheading:20007015-Humans, pubmed-meshheading:20007015-Mice, pubmed-meshheading:20007015-Mice, Nude, pubmed-meshheading:20007015-Middle Aged, pubmed-meshheading:20007015-Orosomucoid, pubmed-meshheading:20007015-Ovarian Neoplasms, pubmed-meshheading:20007015-Xenograft Model Antitumor Assays, pubmed-meshheading:20007015-Young Adult
pubmed:year
2010
pubmed:articleTitle
Clinical pharmacokinetics of the new oral camptothecin gimatecan: the inter-patient variability is related to alpha1-acid glycoprotein plasma levels.
pubmed:affiliation
Istituto di Ricerche Farmacologiche Mario Negri, via La Masa 19, 20156 Milan, Italy. frapolli@marionegri.it
pubmed:publicationType
Journal Article, Clinical Trial, Phase I